Woods R L, Stewart J, Fox R M, Tattersall M H
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1997-9.
Thirty-three patients with a histologically confirmed diagnosis of advanced squamous cell carcinoma of the head and neck were treated with a combination of vincristine, methotrexate, and bleomycin. The regimen was as follows: Day 1, vincristine (2 mg iv) and methotrexate (200 mg/m2 iv over 24 hours); Day 2, bleomycin (15 mg/day by iv infusion for 48 hours). Folinic acid rescue began 36 hours after the start of methotrexate. The regimen was repeated at intervals of 3 weeks. Toxicity was minimal but the overall response rate was only 24% (three complete responses and five partial responses) and the median duration of remission was only 16 weeks overall. The combination of vincristine, methotrexate, and bleomycin in this dosage schedule has a response rate lower than that reported with single-agent treatment of advanced head and neck cancers.
33例经组织学确诊的晚期头颈部鳞状细胞癌患者接受了长春新碱、甲氨蝶呤和博来霉素联合治疗。治疗方案如下：第1天，长春新碱（静脉注射2mg）和甲氨蝶呤（200mg/m²静脉滴注24小时）；第2天，博来霉素（15mg/天静脉输注48小时）。甲氨蝶呤开始给药36小时后开始亚叶酸解救。该方案每3周重复一次。毒性轻微，但总体缓解率仅为24%（3例完全缓解和5例部分缓解），总体缓解期中位数仅为16周。按此剂量方案使用长春新碱、甲氨蝶呤和博来霉素联合治疗的缓解率低于晚期头颈部癌单药治疗报道的缓解率。
